FDA Approves Immunotherapy Drug Combination for People With Most Common Type of Liver Cancer
May 30, 2020
May 30, 2020
LOS ANGELES, California, May 30 -- The Jonsson Comprehensive Cancer Center at the University of California at Los Angeles issued the following news:
For the first time in over a decade, a new drug combination has been approved by the U.S. Food & Drug Administration to treat hepatocellular carcinoma, the most common type of liver cancer, as a first-line treatment.
Researchers found that a combination of atezolizumab, an immunotherapy drug that boosts the body's . . .
For the first time in over a decade, a new drug combination has been approved by the U.S. Food & Drug Administration to treat hepatocellular carcinoma, the most common type of liver cancer, as a first-line treatment.
Researchers found that a combination of atezolizumab, an immunotherapy drug that boosts the body's . . .